Novel frameshift mutation in PURA gene causes severe encephalopathy of unclear cause.
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
20
01
2021
received:
18
09
2020
accepted:
29
01
2021
pubmed:
23
3
2021
medline:
20
1
2022
entrez:
22
3
2021
Statut:
ppublish
Résumé
The etiology of many genetic diseases is challenging. This is especially true for developmental disorders of the central nervous system, since several genes can be involved. Many of such pathologies are considered rare diseases, since they affect less than 1 in 2000 people. Due to their low frequency, they present several difficulties for patients, from the delay in the diagnosis to the lack of treatments. Next-generation sequencing techniques have improved the search for diagnosis in several pathologies. Many studies have shown that the use of whole-exome/genome sequencing in rare Mendelian diseases has a diagnostic yield between 30% and 50% depending on the disease. Here, we present the case of an undiagnosed 6-year-old boy with severe encephalopathy of unclear cause, whose etiological diagnosis was achieved by whole-genome sequencing. We found a novel variant that has not been previously reported in patients nor it has been described in GnomAD. Segregation analysis supports a de novo mutation, since it is not present in healthy parents. The change is predicted to be harmful to protein function, since it falls in the first quarter of the protein producing an altered reading frame and generating a premature stop codon. Additionally, the variant is classified as pathogenic according to ACMG criteria (PVS1, PM2, and PP3). Furthermore, there are several reported frameshift mutations in nearby codons as well as nonsense mutations that are predicted as pathogenic in other studies. We found a novel de novo frameshift mutation in the PURA gene (MIM number 600473), c.151_161del, with sufficient evidence of its pathogenicity.
Sections du résumé
BACKGROUND
The etiology of many genetic diseases is challenging. This is especially true for developmental disorders of the central nervous system, since several genes can be involved. Many of such pathologies are considered rare diseases, since they affect less than 1 in 2000 people. Due to their low frequency, they present several difficulties for patients, from the delay in the diagnosis to the lack of treatments. Next-generation sequencing techniques have improved the search for diagnosis in several pathologies. Many studies have shown that the use of whole-exome/genome sequencing in rare Mendelian diseases has a diagnostic yield between 30% and 50% depending on the disease.
METHODS
Here, we present the case of an undiagnosed 6-year-old boy with severe encephalopathy of unclear cause, whose etiological diagnosis was achieved by whole-genome sequencing.
RESULTS
We found a novel variant that has not been previously reported in patients nor it has been described in GnomAD. Segregation analysis supports a de novo mutation, since it is not present in healthy parents. The change is predicted to be harmful to protein function, since it falls in the first quarter of the protein producing an altered reading frame and generating a premature stop codon. Additionally, the variant is classified as pathogenic according to ACMG criteria (PVS1, PM2, and PP3). Furthermore, there are several reported frameshift mutations in nearby codons as well as nonsense mutations that are predicted as pathogenic in other studies.
CONCLUSION
We found a novel de novo frameshift mutation in the PURA gene (MIM number 600473), c.151_161del, with sufficient evidence of its pathogenicity.
Identifiants
pubmed: 33750045
doi: 10.1002/mgg3.1622
pmc: PMC8172205
doi:
Substances chimiques
DNA-Binding Proteins
0
PURA protein, human
0
Transcription Factors
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1622Informations de copyright
© 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Références
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Am J Med Genet A. 2012 Aug;158A(8):1891-6
pubmed: 22711443
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Bioinformatics. 2014 Nov 1;30(21):3115-7
pubmed: 25028726
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Am J Med Genet A. 2018 Jan;176(1):56-67
pubmed: 29150892
Mol Cytogenet. 2015 Nov 14;8:89
pubmed: 26582469
Am J Med Genet A. 2011 Apr;155A(4):732-6
pubmed: 21594995
Bioinformatics. 2005 Apr 1;21(7):951-60
pubmed: 15531603
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Gene. 2018 Feb 15;643:133-143
pubmed: 29221753
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
pubmed: 12824425
J Cell Physiol. 2013 May;228(5):930-7
pubmed: 23018800
J Med Genet. 2018 Feb;55(2):104-113
pubmed: 29097605
Curr Genomics. 2007 Nov;8(7):429-44
pubmed: 19412416
JAMA. 2014 Nov 12;312(18):1870-9
pubmed: 25326635
NPJ Genom Med. 2016 Jan 13;1:
pubmed: 28567303
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Nat Struct Mol Biol. 2009 Feb;16(2):107-13
pubmed: 19190664
Nucleic Acids Res. 2018 Jul 2;46(W1):W200-W204
pubmed: 29905871
J Med Genet. 2014 Dec;51(12):806-13
pubmed: 25342064
Mol Cell Biol. 2003 Oct;23(19):6857-75
pubmed: 12972605
Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000356
pubmed: 27148565
NPJ Genom Med. 2018 Jul 9;3:16
pubmed: 30002876
Hum Mol Genet. 2012 Feb 1;21(3):473-84
pubmed: 22010047
Elife. 2016 Jan 08;5:
pubmed: 26744780
Am J Hum Genet. 2014 Nov 6;95(5):579-83
pubmed: 25439098
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669